Sterneck Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 131,907 shares of the company’s stock after purchasing an additional 6,702 shares during the quarter. Teva Pharmaceutical Industries Limited makes up about 2.6% of Sterneck Capital Management LLC’s investment portfolio, making the stock its 8th largest holding. Sterneck Capital Management LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $4,382,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Greylin Investment Mangement Inc. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after purchasing an additional 79,300 shares during the period. Financial Counselors Inc. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock valued at $4,671,000 after purchasing an additional 7,571 shares during the period. PGGM Investments lifted its stake in shares of Teva Pharmaceutical Industries Limited by 12.0% in the 2nd quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock valued at $50,763,000 after purchasing an additional 163,292 shares during the period. GAM Holding AG lifted its stake in shares of Teva Pharmaceutical Industries Limited by 23.2% in the 2nd quarter. GAM Holding AG now owns 41,900 shares of the company’s stock valued at $1,392,000 after purchasing an additional 7,900 shares during the period. Finally, Chou Associates Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 134.9% in the 2nd quarter. Chou Associates Management Inc. now owns 505,000 shares of the company’s stock valued at $16,839,000 after purchasing an additional 290,000 shares during the period. Institutional investors own 56.75% of the company’s stock.

WARNING: “Sterneck Capital Management LLC Has $4.38 Million Stake in Teva Pharmaceutical Industries Limited (TEVA)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/10/13/sterneck-capital-management-llc-has-4-38-million-stake-in-teva-pharmaceutical-industries-limited-teva.html.

A number of research firms have recently commented on TEVA. Vetr cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price for the company. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. BidaskClub cut Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup Inc. cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. Finally, Maxim Group reiterated a “hold” rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $27.63.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 2.84% during trading on Friday, hitting $14.72. The stock had a trading volume of 16,323,360 shares. The firm has a 50 day moving average price of $16.76 and a 200 day moving average price of $26.28. The firm’s market cap is $14.96 billion. Teva Pharmaceutical Industries Limited has a 12-month low of $14.30 and a 12-month high of $44.49.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.25 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.24%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.